Published in J Natl Cancer Inst on October 11, 2010
The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS One (2013) 1.22
S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013. Geburtshilfe Frauenheilkd (2013) 1.15
Immunity and immune suppression in human ovarian cancer. Immunotherapy (2011) 1.07
Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med (2013) 1.01
Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. Am J Surg Pathol (2015) 0.91
Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer. Cancer Immunol Immunother (2015) 0.86
The Globalization of Cooperative Groups. Semin Oncol (2015) 0.82
Estimation of expectedness: predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer. Cancer (2014) 0.81
SB225002 promotes mitotic catastrophe in chemo-sensitive and -resistant ovarian cancer cells independent of p53 status in vitro. PLoS One (2013) 0.81
Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma. Int Sch Res Notices (2014) 0.77
Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life. Support Care Cancer (2015) 0.77
Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference. J Gynecol Oncol (2017) 0.75
Effects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study. Medicine (Baltimore) (2016) 0.75
Paclitaxel and Carboplatin (TC) Regimen for Ovarian Cancer. Hosp Pharm (2014) 0.75
Another confirmation of the inactivity of topotecan in ovarian cancer. J Natl Cancer Inst (2010) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83
Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell (2001) 15.05
Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med (1999) 10.16
VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J (1999) 6.62
Large-scale analysis of gene function in Caenorhabditis elegans by high-throughput RNAi. Curr Biol (2001) 6.05
Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest (1998) 5.95
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Stimulation of bone formation in vitro and in rodents by statins. Science (1999) 5.55
Report of a National Workshop on Screening for Cancer of the Cervix. CMAJ (1991) 5.37
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol (2012) 5.32
Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature (2000) 4.93
A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A (1992) 4.77
Activity-dependent action potential invasion and calcium influx into hippocampal CA1 dendrites. Science (1995) 4.29
Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst (2009) 4.24
Environment and development. Earth system science for global sustainability: grand challenges. Science (2010) 3.92
Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res (1998) 3.79
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med (1998) 3.60
Age-dependent impairment of angiogenesis. Circulation (1999) 3.47
Condylomatous lesions of the cervix. II. Cytologic, colposcopic and histopathologic study. Acta Cytol (1977) 3.36
Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer--a meta-analysis. Clin Oncol (R Coll Radiol) (2002) 3.33
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol (2000) 3.33
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol (2004) 3.29
Gene expression profiling of cells, tissues, and developmental stages of the nematode C. elegans. Cold Spring Harb Symp Quant Biol (2003) 3.22
Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol (1993) 3.18
RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer (2006) 3.15
Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology (2000) 2.99
Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol (2002) 2.99
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature (1998) 2.98
Rab11 is required for trans-golgi network-to-plasma membrane transport and a preferential target for GDP dissociation inhibitor. Mol Biol Cell (1998) 2.86
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol (2002) 2.86
Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol (1999) 2.83
Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation (1996) 2.79
Function of the 30 kd protein of tobacco mosaic virus: involvement in cell-to-cell movement and dispensability for replication. EMBO J (1987) 2.78
Calcium action potentials restricted to distal apical dendrites of rat neocortical pyramidal neurons. J Physiol (1997) 2.77
Methylation of histone H3 by coactivator-associated arginine methyltransferase 1. Biochemistry (2001) 2.74
Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities. J Biol Chem (2001) 2.74
Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med (1997) 2.73
Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group. Ultrasound Obstet Gynecol (2000) 2.70
Roles of topoisomerases in maintaining steady-state DNA supercoiling in Escherichia coli. J Biol Chem (2000) 2.58
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol (2010) 2.54
Risk factors for suicide completion in major depression: a case-control study of impulsive and aggressive behaviors in men. Am J Psychiatry (2005) 2.54
Gastric cancer: epidemiology, pathology and treatment. Ann Oncol (2003) 2.53
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2013) 2.53
The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. Genes Dev (1999) 2.52
Transcription elongation factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages. EMBO J (1998) 2.45
Regulated secretion in platelets: identification of elements of the platelet exocytosis machinery. Blood (1997) 2.44
Type II myosin heavy chain encoded by the myo2 gene composes the contractile ring during cytokinesis in Schizosaccharomyces pombe. J Cell Biol (1997) 2.43
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med (1997) 2.31
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.31
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest (2003) 2.30
Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol (1998) 2.29
Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation (1998) 2.25
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer (2006) 2.23
end-1 encodes an apparent GATA factor that specifies the endoderm precursor in Caenorhabditis elegans embryos. Genes Dev (1997) 2.22
The role of water stress in the inactivation of messenger RNA of germinating wheat embryos. Proc Natl Acad Sci U S A (1968) 2.15
Role of diaphragmatic surgery in 69 patients with ovarian carcinoma. Int J Gynecol Cancer (2008) 2.12
X-ray spectra estimation using attenuation measurements from 25 kVp to 18 MV. Med Phys (1999) 2.11
Formulation and physical characterization of large porous particles for inhalation. Pharm Res (1999) 2.10
Efficient interaction of HIV-1 with purified dendritic cells via multiple chemokine coreceptors. J Exp Med (1996) 2.08
Regulation of phosphatidylinositol 3'-kinase by tyrosyl phosphoproteins. Full activation requires occupancy of both SH2 domains in the 85-kDa regulatory subunit. J Biol Chem (1995) 2.06
Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol (2012) 2.04
Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer (2008) 2.03
Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol (1993) 2.00
Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst (2000) 1.99
Quantification of growth factor levels using a simplified method of platelet-rich plasma gel preparation. J Oral Maxillofac Surg (2000) 1.99
Three-dimensional visualization of the rotavirus hemagglutinin structure. Cell (1993) 1.95
HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer (2011) 1.95
Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol Endocrinol (1998) 1.95
Funding Canada's health care system: a tax-based alternative to privatization. CMAJ (1998) 1.92
Resetting the biological clock: mediation of nocturnal circadian shifts by glutamate and NO. Science (1994) 1.88
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet (1998) 1.88
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.87
Protection against vaginal SIV transmission with microencapsulated vaccine. Science (1993) 1.86
Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol (2008) 1.86
Genetic diversity of Pierce's disease strains and other pathotypes of Xylella fastidiosa. Appl Environ Microbiol (2001) 1.85
Lymph node metastases in low-grade endometrial stromal sarcoma. Gynecol Oncol (2005) 1.83
MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone (2004) 1.79
A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. J Clin Pathol (1997) 1.76
Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry (1998) 1.75
Axonal initiation and active dendritic propagation of action potentials in substantia nigra neurons. Neuron (1995) 1.75
A novel mechanism of PKA anchoring revealed by solution structures of anchoring complexes. EMBO J (2001) 1.75